Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
September 05, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
August 28, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
August 12, 2024 16:05 ET
|
Perspective Therapeutics, Inc.
Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trialsOn track to advance multiple pre-IND assets into the clinic in the next 12-18 monthsMaking continued...
Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
July 30, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
July 22, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
June 12, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
June 11, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
June 10, 2024 16:10 ET
|
Perspective Therapeutics, Inc.
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 24, 2024 08:01 ET
|
Perspective Therapeutics, Inc.
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
May 20, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...